Celltrion USA Patent-Cliff Exposure & CMS Drug Spending Portfolio
Celltrion USA (US): 3 reconciled FDA prescription therapies, $23.8M 2024 CMS Part D & Medicaid spend, and $3,277 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $23.8M |
| 2024 Medicare Part D Spend | $22.5M |
| 2024 Medicaid Spend | $1.3M |
| California HCAI SB 17 Filings | Specialty launch notice ($3,277 intro WAC) |